One of the seven key scientific priorities identified in the road map on HIV cure research is to 'determine the host mechanisms that control HIV replication in the absence of therapy'. This review summarizes the recent work in genomics and in epigenetic control of viral replication that is relevant for this mission.
INTRODUCTION
The global scientific strategy of the International HIV Society 'Towards an HIV cure' [1] identified the potential of genomics for the understanding of mechanisms of latency. This includes the analysis of the steps in the establishment of viral transcriptional silencing as well as the steps that allow reactivation of viral transcription: the site of viral DNA integration, the chromatin environment of the integrated provirus and the availability of transcription factors. These components can be investigated through genomic, transcriptomic and epigenomic analyses.
Currently, two models are used to describe how HIV establishes latency in resting CD4 þ T cells [2, 3] . The first model suggests that activated cells are first infected by HIV, and even though the majority of them are productively infected and die within a few days, a minority of them revert to a resting memory state following the natural biology of CD4 þ T cells. Although the mechanisms leading to cell memory are yet unclear, it is accompanied by cellular changes at the transcriptome and proteome levels (that are yet to be completely described), that in turn impact the viral transcription, ultimately repressing it. The second model suggests that, even if poorly efficient, HIV is able to directly infect the resting CD4 þ T cells. Initial studies on HIV latency used different models based on cell lines, as primary cell cultures were difficult and short lived. However, in the recent years, multiple models using primary cells -derived from different CD4 þ T-cell subsets -have been developed that yield sufficient amounts of cells, thereby allowing investigation that recapitulate the events that may occur in vivo [4 & ]. Latency models using T-cell lines and primary CD4 þ T cells are also used for the screening of molecules that promote viral transcription [5] [6] [7] [8] .
That multiple compounds reactivate viral transcription from latently infected cells in vitro may reflect the various mechanisms involved in viral transcriptional control [6, 9] . These include epigenetic regulation (such as histone acetylation and DNA methylation) and immune modulation (such as T-cell receptor engagement and protein kinase C signaling) [6, 9] . Some of the agents are moving forward to clinical assessment [1, 9, 10] .
This review presents the opportunities in the use of novel technology for the analysis of the contribution of host factors to the viral life cycle in productive infection, and of viral integration site and host factors (including epigenetic control of the viral promoter) to the establishment of and reactivation from latency ( Fig. 1) .
DYNAMIC ASPECTS OF THE VIRAL LIFE CYCLE
HIV-1 is fully dependent of the cellular machinery to complete the replication cycle. The infected cell undergoes a profound modification of its physiology. Although the interaction between HIV-1 and the host cell has been extensively studied [11] , previous analyses did not assess all the relevant steps of viral replication with a dynamic perspective. Transcriptome analyses used microarray technology in cross-sectional experiments, generally at the completion of the viral replication cycle (24-48 h) [12] . The transcriptional status of genes contributes to the preferential integration of proviruses [13] ; however, there are limited data on how the viral integration contributes to host transcription at genomewide level. Analyses have also been hampered by the heterogeneity of the infectious system models, in which the transcriptome profile reflects contribution by the infected and uninfected cells. The first models of productive and latent infection use cell lines and primary CD4 þ T-cell subsets.
There is increasing recognition of the role of antisense transcription of the HIV genome in regulating viral gene expression.
Integration site, orientation and the surrounding host genetic features influence viral transcription efficiency.
Single-cell analysis is needed to assess the role of integration features on viral transcription and the other aspects of heterogeneity in the latent cell population. Analyses underscored the features of the successful viral replication occurring despite a profound perturbation of the cell at the transcriptional level. This type of work -currently performed in cell linesrepresents a referential resource that can be contrasted across cellular systems and viral strains, and that can be extended to study the establishment of and reactivation from viral latency. The interpretation of these complex sets of data is becoming feasible in the frame of systems biology; however, functional studies will be needed before this information can impact our knowledge on HIV infection in practical terms.
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SPATIAL FEATURES OF HIV INTEGRATION
HIV inserts its viral genome nonrandomly into the host DNA, strongly favoring active transcription units, thereby promoting efficient viral transcription and productive infection [13, 21] þ T cells [24, 26] . Analysis of viral transcription performed upon targeted insertion of the viral genome in the actively transcribed gene (HPRT) suggested that viral transcription was inhibited when viral and cellular transcription were in convergent orientations, whereas it was enhanced when viral and cellular transcription were in the same orientation [27] . In contrast, in a primary CD4
þ T-cell model of latency, viral integration in the same orientation as hosting cellular genes was enriched in latent cells, suggesting that repression of viral transcription was enriched upon promoter occlusion in this system [28 & ]. These data argue for a contribution of integration site location and surrounding host genomic features to viral transcription efficiency; however, to which extent each of these factors influences latency remains to be clarified. Progress in single-cell analysis could allow a more precise evaluation of the influence of viral genome integration site on viral transcription. Indeed, various CD4 þ T populations have different capacity to support the reservoir of HIV infection. These may result in significant loss of homogeneity in the population of latently infected cells, emphasizing the interest of examining cell-to-cell heterogeneity in single-cell assays. There are now different techniques that make use of microfluidic platforms and highly multiplexed assays that allow the analysis of expression of 20-800 genes at the single-cell level [29, 30] . Diversity in integration site may modulate the efficacy of reactivating agents used in in-vitro models of latency [6, 9, 31] .
TRANSCRIPTOME AND PROTEOME MODIFICATIONS DURING LATENCY AND REACTIVATION
Some of the recent applications of transcriptome analysis aimed at the characterization of the pattern of host expression after the control of viral replication in vivo [12, 32, 33] . A similar approach was applied to the characterization of host expression profile in elite controllers. The transcriptome profile in CD4
þ T cells of successfully treated individuals is similar to that of elite controllers. Detailed analysis of specific cell subsets may, however, demonstrate residual abnormalities in the gene regulation among individuals receiving antiretroviral treatment compared with healthy blood donors [34] . These studies, however, capture population effects that reflect the overall consequences of immune activation and the contribution of transcriptomes of noninfected cells.
Comparison of resting and activated CD4 þ T-cell transcriptomes identified differentially expressed and alternatively spliced genes [35] [36] [37] . Of note, these studies used resting cells and then stimulated them to activated cells; however, no study describes the contrary, that is, activated to resting. Assessing the transcriptome changes from activated infected cells to resting cells is needed to better characterize the sequence of events leading to viral transcriptional silencing.
Resting and activated CD4 þ T cells also differ in their proteome composition. Although no large-scale proteome study was performed so far to compare CD4 þ T cells in these two states, the differential expression or localization of specific proteins has been reported. More particularly, the pool of available transcription factors in the nucleus regulating viral transcription varies between resting and activated CD4 þ T cells [4 & ,38] . Examples include the nuclear availability of NF-kB in the activated cells contrasts with it being sequestered in the cytoplasm of quiescent CD4 þ T cells; the high amount of CBF-1, an inhibitor of LTR-driven viral transcription, in resting cells appears in reduced amounts in activated cells [38, 39] ; and the degradation of cyclinT1 and the absence of T186 phosphorylation on cdk9, the units composing pTEFb kinase, in resting cells, whereas abundantly present in activated cells [40] .
EPIGENETIC MODIFICATIONS OF THE HIV PROMOTER
As the viral genome integrates into the host DNA, it is chromatinized and is subject to cellular epigenetic regulation. The chromatin organization at the viral LTR promoter has been investigated, identifying precisely positioned nucleosomes [41,42 && ]: nuc-0 at position À415 to À255 (compared with the transcriptional start site, TSS, þ1), a nucleosome-free region or with poorly positioned nucleosomes (-255 to -3/þ10); nuc-1 at þ10 to þ155, a nucleosome-free region (þ155 to þ265); and nuc-2 at þ265 to þ409. Nucleosome-free regions present binding sites for multiple transcriptional regulators, whereas nuc-1 is positioned just after the TSS, blocking viral transcription. Nuc-1 has to be displaced or disrupted to allow successful transcriptional elongation. Thus, the identity of bound transcriptional regulators as well as histone posttranslational modifications and DNA methylation dictate viral gene expression [4 & ]. Binding of available specific transcription factors recruit chromatin-modifying enzymes that shape the chromatin environment at the viral LTR and participate in the regulation of viral transcription activity. Studies using chromatin immunoprecipitation (ChIP) showed that histone posttranslational modifications, specifically acetylation and methylation, are correlated with the viral transcriptional activity [4 & ,42 && , [43] [44] . DNA methylation in the CpG islands surrounding the viral transcription start site is associated with viral gene silencing [3, 45, 46] . DNA methylation is currently thought of as the last step of repression of gene expression, contributing to a compact chromatin structure and decreasing the efficiency of some reactivating agents. These data confirm that specific transcription factors, histone modifications and DNA methylation levels at the viral promoter determine the efficiency of viral gene expression. However, most studies compare activated versus resting cells at one single timepoint focusing on specific histone posttranslational modifications, without the sequential evaluation of chromatin modifications.
CONCLUSION
Genomic analyses are well suited for the study of viral latency and reactivation as a dynamic process. As such, these approaches respond to several of the priorities of the HIV Cure Research agenda published in 2012 [1] (Fig. 2) , in particular, the call for detailed understanding of the transcriptional features of the process of latency and the possibility to use novel technologies. Specific issues in which novel technology may be of importance include assessment of the extent of 'true' latency, that is the degree of HIV transcriptional silence; the role of spatial features of viral integration contributing to transcription; the identification of candidate biomarkers of latency; and the characterization of successful activation programs leading to viral expression at population and single-cell level. 1. Parallel assessment of existing in-vitro latency models and patient-derived latently infected cells. Some potential approaches include:
a. Deep-sequencing of latently infected cells -using latently infected cells from in-vitro models and patient-derived cells.
b. Validation of the phenotype/expression profile of the latently infected cell. This includes testing of 'expression modules' (short list of genes associated with the study profile), and development of single cell assays.
2. Characterization of viral transcripts (if any) associated with latency, or with entry/exit from latency -including antisense transcripts with a possible regulatory role.
3. Clinical and biological determinants of reservoir size. This could first be assessed using large well characterized cohort studies comparing reservoir size to a range of clinical parameters. The use of genomics, transcriptomics and other population-based approaches should also be considered.
4. Adaptation of identified candidate markers for high-throughput screening (FACS, gene expression assays).
5. Identification of host factors that determine the size of the reservoir. 
